User:Erin May/Sandbox 1

This structure is the form of Major Prion Protein as it appears in an non-diseased individual. This is a monomer in healthy tissues. The majority of this 3D structure is .

The following residue alterations confer increased susceptibility to the unfolding of alpha helices characteristic of spongiform encephalopathies.

Residue 129 Val-->Met confers increased susceptibility to the catalytic unfolding of the alpha helices characteristic of spongiform encephalopathies. In monomeric form, , does not offer a possible mechanism of unfolding or aggregation. As of January 2010, only individuals with homozygous Metionine129 had been diagnosed with infectious Creutzfeldt–Jakob disease.

exhibit species specific residues. This region is most variable between species. Residue shifts in this section increase or decrease susceptibility from inter-species transmission of TSE's. The more similar this region is between species, the more likely each are able to transfer infectious prions between the two.^[4]

. This residue shift changes the surface electrostatic potential in a way which alters its interactions with other prion proteins as well as chaperone proteins. The Lys residue in position 200 is found in the infectious form of Creutzfeldt–Jakob disease. Those who have Lysine in the 200 position who live long enough will develop a spontaneous form of Creutzfeldt–Jakob disease.^[5]

Image:Http://www.jbc.org/content/275/43/33650/F4.large.jpg ^[5]

The in the monomeric form must all be broken during the conformational change from PrP^C to PrP^Sc. ^[6]

The majority of this structure is . The following residues are not visible in the PrP^Sc shown. These residues are not part of the beta sheets of the unraveled prion protein, yet they are important to the transference of TSEs. The dimer form of Human Prion Protein shows where these residues make their influence:

129 Val-->Met (susceptibility to Creutzfeldt–Jakob disease).

Residues R164 to S170 (variable region between species)^[4]

200 Glu-->Lys (present in infectious and spontaneous form of Creutzfeldt–Jakob disease)^[5]

The Cystine residues which were formerly part of disulfide bonds have been reduced catalytically without any chemical reducing agent. ^[6]

The , shown above, alter the function of Major Prion Protein's ability to re-fold, however their positions on the wild-type monomer and fully unfolded PrP^Sc, do not illustrate a clear mechanism for propagation. The dimer brings light to these residues influence on the infectious qualities of the disease causing residues.

It is theorized from this dimeric structure that the dimerization is the first step in amyloid formation and the presence of these dimers could possibly speed up the aggregation of PrP^Sc.

The following interactions and residue switching portray possible catalytic sites:

Residues 129, 200, and 164 to 170 are shown to exist right at the dimer interfaces (as noted in the previous structures). The location of these residues within the dimer indicates that their key operation is found somewhere in the dimerization process.

Helix 1 (Ser 143−Tyr 157) exists at the . Many nonpolar residues form Van der Waals attractions. Acidic and mostly negative residues are shown in blue. Basic and mostly positive residues are shown in red. The interactions between these also stabilize the dimer interface.

Helix 2 (Asn 171−Thr 188) is to the C-terminal helix 3 (Thr 199−Tyr 225). Van der Waals forces are here between such nonpolar residues as valine, isoleucene, and nonpolar sections as histadine, methionine, and glutamic acid.^[6]

The (residues 189-198) is where the actual unfolding has taken place.

More Van der Waals and electrostatic forces occur between the of the same molecule. These interactions would not be able to occur in the monomer.

Hydrogen bonding between the dimers exist: Thr188 O−Gly195 N, Thr190 O−Lys194 N and Thr192 O−Thr192 N

between Asp 202 and Thr 199 stabilize the dimeric structure.

Arg 220 hydrogen bonds are located at either end of helix 3, form interchain hydrogen bonds that confer specificity to the interaction.

Due to the importance of initial dimerization in the formation of prion aggregates, the step of dimerization presents a known step for treatments to target.^[6]